Mark A. Ator

4.4k total citations
91 papers, 3.1k citations indexed

About

Mark A. Ator is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mark A. Ator has authored 91 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 33 papers in Oncology and 16 papers in Immunology. Recurrent topics in Mark A. Ator's work include Peptidase Inhibition and Analysis (10 papers), Calpain Protease Function and Regulation (9 papers) and Cancer therapeutics and mechanisms (9 papers). Mark A. Ator is often cited by papers focused on Peptidase Inhibition and Analysis (10 papers), Calpain Protease Function and Regulation (9 papers) and Cancer therapeutics and mechanisms (9 papers). Mark A. Ator collaborates with scholars based in United States, France and Germany. Mark A. Ator's co-authors include P.R. Ortiz de Montellano, Roland E. Dolle, Thelma S. Angeles, Carla T. Helaszek, J. Stubbe, JoAnne Stubbe, Bruce Ruggeri, Robert L. Hudkins, John P. Mallamo and Stanley J. Schmidt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Mark A. Ator

91 papers receiving 2.9k citations

Peers

Countries citing papers authored by Mark A. Ator

Since Specialization

Citations

This map shows the geographic impact of Mark A. Ator's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Ator with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Ator more than expected).

Fields of papers citing papers by Mark A. Ator

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Ator. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Ator. The network helps show where Mark A. Ator may publish in the future.

Co-authorship network of co-authors of Mark A. Ator

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Ator. A scholar is included among the top collaborators of Mark A. Ator based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Ator. Mark A. Ator is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Cellular Assay for Inhibitors of the Fatty Acid Biosynthetic Pathway Using Scintillating Microplates 2015 ·Assay and Drug Development Technologies ·(unknown), Jennifer L. Mason, (unknown), (unknown), Mark A. Ator, Thelma S. Angeles	1
2	Comparison of LanthaScreen Eu Kinase Binding Assay and Surface Plasmon Resonance Method in Elucidating the Binding Kinetics of Focal Adhesion Kinase Inhibitors 2012 ·Assay and Drug Development Technologies ·Jennifer L. Mason, (unknown), Jean Husten, (unknown), Mark S. Albom, Sheryl L. Meyer, Mark A. Ator, Thelma S. Angeles	7
3	Time-Resolved Fluorescence Resonance Energy Transfer as a Versatile Tool in the Development of Homogeneous Cellular Kinase Assays 2012 ·Assay and Drug Development Technologies ·(unknown), (unknown), Jennifer L. Mason, Mark S. Albom, S. N. Prasanna Murthy, Sheryl L. Meyer, Mark A. Ator, Thelma S. Angeles, Jean Husten	1
4	Wake-promoting agents: Search for next generation modafinil: Part II 2012 ·Bioorganic & Medicinal Chemistry Letters ·Derek W. Dunn, (unknown), (unknown), (unknown), (unknown), (unknown), John A. Gruner, Edward R. Bacon, Mark A. Ator, Sankar Chatterjee	2
5	Proteasome inhibitors for cancer therapy 2012 ·Bioorganic & Medicinal Chemistry ·Mohamed Iqbal, (unknown), Derek Dunn, Satish Mallya, Jean Husten, Mark A. Ator, Sankar Chatterjee	8
6	Wake promoting agents: Search for next generation modafinil, lessons learned: Part III 2012 ·Bioorganic & Medicinal Chemistry Letters ·Derek Dunn, (unknown), Mohamed Iqbal, Val R. Marcy, (unknown), B. E. Jones, Lisa D. Aimone, John A. Gruner, Mark A. Ator, Edward R. Bacon, Sankar Chatterjee	13
7	CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers 2011 ·Molecular Cancer Therapeutics ·Mangeng Cheng, Matthew R. Quail, Diane E. Gingrich, Gregory R. Ott, Lihui Lü, Weihua Wan, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, (unknown), Rodolfo Machiorlatti, (unknown), Mark A. Ator, Bruce D. Dorsey, Giorgio Inghirami, Bruce Ruggeri	59
8	CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Rita Raddatz, Robert L. Hudkins, Joanne R. Mathiasen, John A. Gruner, Dorothy G. Flood, Lisa D. Aimone, (unknown), Hervé Schaffhauser, Emir Duzic, Maciej Gąsior, Donna Bozyczko‐Coyne, Michael J. Marino, Mark A. Ator, Edward R. Bacon, John P. Mallamo, Michael Williams	52
9	Wake-promoting agents: Search for next generation modafinil: Part I 2011 ·Bioorganic & Medicinal Chemistry Letters ·Derek Dunn, (unknown), Mohamed Iqbal, (unknown), (unknown), (unknown), John A. Gruner, Edward R. Bacon, Mark A. Ator, Sankar Chatterjee	7
10	Modification of CellSensor irf1- bla TF-1 and irf1- bla HEL Assays for Direct Comparison of Wild-Type JAK2 and JAK2 V617F Inhibition 2010 ·Assay and Drug Development Technologies ·Jennifer L. Mason, Beverly P. Holskin, Kristen A. Murray, Sheryl L. Meyer, Kevin J. Wells‐Knecht, Mark A. Ator, Thelma S. Angeles	3
11	CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models 2007 ·Molecular Cancer Therapeutics ·Bruce Ruggeri, Ted L. Underiner, Diane E. Gingrich, Robert L. Hudkins, Thelma S. Angeles, Mark S. Albom, Hong Chang, Candy Robinson, Kathryn Hunter, Paweł Dobrzański, Susan Jones‐Bolin, Lisa D. Aimone, Mark A. Ator, Jean‐Marc Herbert, Françoise Bono, Paul Schaefer, Pierre Casellas, (unknown), John P. Mallamo, Jeffry L. Vaught	2
12	Novel poly(ADP-ribose) polymerase-1 inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Derek Dunn, Jean Husten, Mark A. Ator, Sankar Chatterjee	20
13	The selective PARP inhibitor, CEP-8983 exhibits significant chemosensitization in combination with TMZ and SN38 against chemoresistant tumor cell lines and xenografts 2005 ·Cancer Research ·Sheila Miknyoczki, (unknown), (unknown), Jennifer V. Grobelny, (unknown), (unknown), Allison L. Zulli, Mark A. Ator, Jean Husten, Robert L. Hudkins, Ralph E. Parchment, (unknown)	1
14	Synthesis and structure–activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Ming Tao, (unknown), Ron Bihovsky, Gregory J. Wells, Jean Husten, Mark A. Ator, Robert L. Hudkins	41
15	P2-achiral, P'-extended α-ketoamide inhibitors of calpain I 1999 ·Bioorganic & Medicinal Chemistry Letters ·Sankar Chatterjee, Derek Dunn, Ming Tao, Gregory J. Wells, (unknown), Ron Bihovsky, Mark A. Ator, Robert Siman, John P. Mallamo	35
16	A Sensitive, Continuously Recording Fluorogenic Assay for Calpain 1998 ·Biochemical and Biophysical Research Communications ·Satish Mallya, Sheryl L. Meyer, Donna Bozyczko‐Coyne, Robert Siman, Mark A. Ator	10
17	P2-proline-derived inhibitors of calpain I 1998 ·Bioorganic & Medicinal Chemistry Letters ·Rabindranath Tripathy, (unknown), Derek Dunn, Shobha E. Senadhi, Mark A. Ator, Sankar Chatterjee	10
18	σRecognition sites in brain and peripheral tissues Characterization and effects of cytochrome P450 inhibitors 1994 ·Biochemical Pharmacology ·Diane L. DeHaven‐Hudkins, Lorraine F. Lanyon, (unknown), Mark A. Ator	16
19	Synthesis, specificity, and antifungal activity of inhibitors of the Candida albicans .DELTA.24-sterol methyltransferase 1992 ·Journal of Medicinal Chemistry ·Mark A. Ator, Stanley J. Schmidt, Jerry L. Adams, Roland E. Dolle, Lawrence I. Kruse, (unknown), (unknown)	39
20	Mechanism and inhibition of .DELTA.24-sterol methyltransferase from Candida albicans and Candida tropicalis 1989 ·Biochemistry ·Mark A. Ator, Stanley J. Schmidt, Jerry L. Adams, Roland E. Dolle	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact